Drug-cytokine interactions: Focus on cyclosporine

Pharmacotherapy

Volumn 16, Issue 3 I, 1996, Pages 401-408

  Liao, Janice S ^a   Reiss, William G ^b  

^a ST LOUIS COLLEGE OF PHARMACY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; AZATHIOPRINE; BETA INTERFERON; CD3 ANTIGEN; CYCLOSPORIN; CYTOCHROME P450; CYTOKINE; DILTIAZEM; FLUCONAZOLE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; ITRACONAZOLE; KETOCONAZOLE; MONOCLONAL ANTIBODY; NICARDIPINE; OKT 3; TACROLIMUS; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; VERAPAMIL;

ANTIGEN PRESENTATION; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME INHIBITION; GRAFT REJECTION; HUMAN; IMMUNOPHARMACOLOGY; NONHUMAN; REVIEW; T LYMPHOCYTE; TRANSPLANTATION;

ANIMALS; CYCLOSPORINE; CYTOKINES; DRUG INTERACTIONS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 0030014908     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Schmidt J, Fleibner S, Heiman-Weitschat I, et al. Effect of corticosteroids, cyclosporin A, and methotrexate on cytokine release from monocytes and T-cell subsets. Immunopharmacology 1994;27:173-9.
2. Kalo M, Schleimer RP. Antiinflammatory steroids inhibit granulocyte/macrophage colony-stimulating factor production by human lung tissue. Lung 1994;172(2):113-24.
3. Rosenstein ED, Kunicka J, Kramer N, Goldstein G. Modification of cytokine production by piroxicam. J Rheumatol 1994;21(5):901-4.
4. Okuno H, Takasu M, Kuno H, et al. Depression of drug-metabolizing activity in the human liver by interferon-beta. Hepatology 1993;17(1):65-9.
5. Shedlofsky SI, Israel BC, McClain CJ, et al. Endotoxin administration to humans inhibits hepatic cytochrome P-450-mediated drug metabolism. J Clin Invest 1994;94:2209-14.
6. Armstrong SG, Renton KW. Factors involved in the down-regulation of cytochrome P-450 during Listeria monocytogenes infection. Int J Immunopharmacol 1994;16(9):747-54.
7. Coleman RM, Lombard MF, Sicard RE. Fundamental immunology, 2nd ed. Dubuque, IA:Wm. C. Brown, 1992.
8. Roitt I, Brotstoff J, Male D. Immunology, 3rd ed. London:CV Mosby, 1993.
9. Van der Poll T, Lowry SF. Tumor necrosis factor in sepsis:mediator of multiple organ failure or essential part of host defense? Shock 1995;3(1):1-12.
10. Belosevic M, Finbloom DS, Meltzer MS, Nacy CA. IL-2:a cofactor for induction of activated macrophage resistance to infection. J Immunol 1990;145(3):831-9.
11. Bertagnolli M, Herrmann S. IL-7 supports the generation of cytotoxic T lymphocytes from thymocytes. Multiple lymphokines required for proliferation and cytotoxicity. J Immunol 1990;145(6):1706-12.
12. Schmitt E, Beuscher HU, Huels C, et al. IL-1 serves as a secondary signal for IL-9 expression. J Immunol 1991;147(11):3848-54.
13. Bruton JK, Koeller JM. Recombinant interleukin-2. Pharmacotherapy 1994;14(6):635-56.
14. Panitch HS, Bever CT. Clinical trials of interferons in multiple sclerosis. What have we learned? J Neuroimmunol 1993;46(1-2):155-64.
15. McEvoy GK, Litvak K, Welsh OH, eds. AHFS 94 drug information. Bethesda, MD:American Society of Hospital Pharmacists, 1994:2473-8.
16. Strom TB. Molecular immunology and immunopharmacology of allograft rejection. Kidney Int 1992;42(38):S182-7.
17. Wiederrecht G, Lam E, Hung S, Martin M, Sigal N. The mechanism of action of FK-506 and cyclosporine A. Ann NY Acad Sci 1993;696:9-19.
18. Faulds D, Goa KL, Benfield P. Cyclosporin:a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 1993;45(6):953-1040.
19. Yee GC, McGuire TR. Pharmacokinetic drug interactions with cyclosporin. Part 1. Clin Pharmacokinet 1990;19(4):319-32.
20. Peters DH, Fitton A, Plosker GL, Faulds D. Tacrolimus:a review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 1993;46(4):746-94.
21. Todd PA, Brogden RN. Muromonab CD3:a review of its pharmacology and therapeutic potential. Drugs 1989;37:871-99.
22. Rossi SJ, Schroeder TJ, Hariharan S, First MR. Prevention and management of the adverse effects associated with immunosuppressive therapy. Drug Safety 1993;9(2):104-31.
23. Evans WE, Schentag JJ, Jusko WJ. Applied pharmacokinetics:principles of therapeutic drug monitoring, 3rd ed. Vancouver, WA:Applied Therapeutics, 1992.
24. Merion RM, Gorski DH, Burtch CD, et al. Bile refeeding after liver transplantation and avoidance of intravenous cyclosporine. Surgery 1989;106(4):604-9.
25. Cooney GF, Fiel SB, Shaw LM, Cavarocchi NC. Cyclosporine bioavailability in heart-lung transplant candidates with cystic fibrosis. Transplantation 1990;49:821.
26. Kronbach T, Fischer V, Meyer UA. Cyclosporine metabolism in human liver:identification of a cytochrome P-450 III gen family as the major cyclosporine metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988;43:630-5.
27. Watkins PB, Wrighton SA, Schuetz EG, et al. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest 1987;80:1029-36.
28. Kolars JC, Lown KS, Schmiedlin-Ren P, et al. CYP3A gene expression in human gut epithelium. Pharmacogenetics 1994;4:247-59.
29. Slaughter RL, Edwards DJ. Recent advances:the cytochrome P-450 enzymes. Ann Pharmacother 1995;29:619-24.
30. Quesniaux VF. Immunosuppressants:tools to investigate the physiological role of cytokines. BioEssays 1993;15(11):731-9.
31. Andersson J, Nagy S, Groth CG, Andersson U. Effects of FK506 and cyclosporin A on cytokine production studied in vitro at a single-cell level. Immunology 1992;75:136-42.
32. Hatfield SM, Roehm NW. Cyclosporine and FK506 inhibition of murine mast cell cytokine production. J Pharm Exp Ther 1992;260(2):680-8.
33. Chen YL, Vraux VL, Leneveu A, et al. Acute phase response, interleukin-6, and alteration of cyclosporine pharmacokinetics. Clin Pharmacol Ther 1994;55(6):649-60.
34. Fukuda Y, Ishida N, Noguchi T, et al. Interleukin-6 down regulates the expression of transcripts encoding cytochrome P-450 IA1, IA2, and IIIA3 in human hepatoma cells. Biochem Biophys Res Commun 1992;184(2):960-5.
35. Abdel-Razzak Z, Loyer P, Fautrel A, et al. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 1993;44:707-15.
36. Zhao XM, Frist WH, Yeoh TK, Miller GG. Expression of cytokine genes in human cardiac allografts:correlation of IL-6 and transforming growth factor-beta (TGF-B) with histological rejection. Clin Exp Immunol 1993;93:448-51.
37. Pannentier JH, Kremers P, Ferrai L, Batt AM, Gielen JE, Siest G. Repression of cytochrome P-450 by cytokines:IL-1 beta counteracts clofibric acid induction of CYP4A in cultured fetal rat hepatocytes. Cell Biol Toxicol 1993;9(3):307-13.
38. Sakai H, Okamoto T, Kikkawa Y. Suppression of hepatic drug metabolism by the interferon inducer, polyriboinosinic acid:polyribocitidylic acid. J Pharmacol Exp Ther 1992;263(1):381-6.
39. Trautwein C, Ramadori G, Gerken G, Meyer zum Buschenfelde KH, Manns M. Regulation of cytochrome P-450 IID by acute phase mediators in C3H/HeJ mice. Biochem Biophys Res Commun 1992;182(2):617-23.
40. Williams JF, William JB, Sinclair JF, Sinclair PR. Effect of interleukin 6 on phenobarbital induction of cytochrome P-450IIB in cultured rat hepatocytes. Biochem Biophy Res Commun 1991;178(3):1049-55.
41. Williams JF. Cytochrome P-450 isoforms. Regulation during infection, inflammation and by cytokines. J Florida Med Assoc 1991;78(8):517-19.
42. Fukuda Y, Sassa S. Suppression of cytochrome P-450IA1 by interleukin-6 in human HepG2 hepatoma cells. Biochem Pharmacol 1994;47:1187-95.
43. 1) in the hamster. Biochem Pharmacol 1989;38:439-47.
44. Yoshimura N, Ika T, Kahan B. Sequential determination of serum interleukin 6 levels as an immunodiagnostic tool to differentiate rejection from nephrotoxicity in renal allograft recipients. Transplantation 1991;51(1):172-6.
45. Yoshida Y, Iwaki Y, Pham S, et al. Benefits of post-transplantation monitoring of interleukin 6 in lung transplantation. Ann Thorac Surg 1993;55:89-93.
46. Reiss WG, Gidal BE, Spencer NW, et al. Changes in IL-6 concentrations following epilepsy surgery [abstr]. Pharmacotherapy 1995;15:393.